Malaria: treatment.
Winstanley
P
P
Department of Pharmacology and Therapeutics, University of Liverpool.
D000328:Adult; D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D053626:Atovaquone; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008288:Malaria / Q000175:diagnosis / Q000628:therapy*; D016778:Malaria, Falciparum / Q000175:diagnosis / Q000628:therapy; D016780:Malaria, Vivax / Q000175:diagnosis / Q000628:therapy; D008297:Male; D015767:Mefloquine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D009285:Naphthoquinones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010616:Phenanthrenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000188:drug therapy; D002727:Proguanil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011739:Pyrimethamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011803:Quinine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013413:Sulfadoxine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors
D000962:Antimalarials; D009285:Naphthoquinones; D010616:Phenanthrenes; D013413:Sulfadoxine; D011803:Quinine; C023768:halofantrine; D002727:Proguanil; D015767:Mefloquine; D053626:Atovaquone; D011739:Pyrimethamine